Summary
Boston Scientific Corporation (BSX) filed an amendment to its Form 8-K on May 5, 2015, primarily to correct errors in its previously issued Investor Presentation. The original presentation, shared on May 1, 2015, contained inaccuracies regarding organic revenue goals for 2017 and 2018-2019, as well as as-reported revenue guidance for 2015. This amended filing provides the corrected slides to ensure accurate information is available to investors. The primary focus of this filing is a procedural correction of data points. Investors should note that the core business and strategic direction of Boston Scientific remain as previously communicated, but this update addresses specific numerical targets and guidance that were erroneously presented. The company is reiterating its commitment to transparency by promptly correcting these discrepancies.
Key Highlights
- 1Amendment to a previous 8-K filing from May 1, 2015.
- 2Correction of errors in the Investor Day presentation slides.
- 3Specifically addresses inaccuracies in organic revenue goals for 2017 and 2018-2019.
- 4Corrects an error in the as-reported revenue guidance for 2015.
- 5The filing provides corrected slides (Exhibit 99.1) for investor review.
- 6Information furnished, not deemed 'filed' under Section 18 of the Exchange Act.
- 7No new material information beyond the correction of prior data is being disclosed.